Abstract
We compared the effects of telmisartan and olmesartan in 20 patients with chronic heart failure and metabolic syndrome. The subjects underwent once-daily 40 mg telmisartan for at least 3 months before switching to once-daily 20 mg olmesartan for the next 3 months (post 1). They were then treated with 3 months of once-daily 40 mg telmisartan (post 2). Systolic and diastolic blood pressure in the early morning, plasma B-type natriuretic peptide, serum total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were increased at post 1 (p<0.005, p<0.05, p<0.05, p<0.05, p<0.05, and p<0.005 vs. baseline, respectively) before returning to their baseline values at post 2. The changes in plasma B-type natriuretic peptide levels correlated significantly with the shifts in systolic and diastolic blood pressure in the early morning at posts 1 and 2. Meanwhile, there were no fluctuations in either blood pressure in the late evening or in the outpatient room; nor were there fluctuations in heart rate. Simultaneously, neither serum high-density lipoprotein cholesterol nor fasting blood sugar levels differed significantly between posts. Moreover, telmisartan had more beneficial effects on glucose and lipid profiles in patients with relatively high HbA1c, serum total and low-density lipoprotein cholesterol, and triglyceride levels. Therefore, we concluded that telmisartan was more beneficial than olmesartan for controlling blood pressure in the early morning, as well as for improving glucose and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.
Similar content being viewed by others
Article PDF
References
Mancia G, De Backer G, Dominiczak A, et al, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology : 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.
Tislér A, Dunai A, Keszei A, et al: Primary-care physicians' views about the use of home/self blood pressure monitoring: nationwide survey in Hungary. J Hypertens 2006; 24: 1729–1735.
Shimizu M, Shibasaki S, Kario K : The value of home blood pressure monitoring. Curr Hypertens Rep 2006; 8: 363–367.
Chrysant SG, Chrysant GS, Desai A : Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 2005; 19: 173–183.
Kakuta H, Sudoh K, Sasamata M, Yamagishi S : Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41–46.
Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H : Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203–210.
White WB, Lacourciere Y, Davidai G : Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347–353.
Ford ES : Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778.
Lorenzo C, Williams K, Hunt KJ, Haffner SM : The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8–13.
Galassi A, Reynolds K, He J : Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812–819.
Nelson MR : Managing ‘metabolic syndrome’ and multiple risk factors. Aust Fam Physician 2004; 33: 201–205.
Kurtz TW : New treatment strategies for patients with hypertension and insulin resistance. Am J Med 2006; 119 ( Suppl 1): S24–S30.
Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993–1002.
Kurtz TW, Pravenec M : Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253–2261.
Schupp M, Janke J, Clasen R, Unger T, Kintsher U : Angiotensin type 1 receptor blockers induce peroxisome proliferators−activated receptor-gamma activity. Circulation 2004; 109: 2054–2057.
Lehman JM, Moore JB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA : An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators−activated receptor γ (PPAR γ). J Biol Chem 1995; 270: 12953–12956.
Schiffrin EL, Amiri F, Benkirane K, Igralz M, Diep QN : Peroxisome proliferators−activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664–668.
National Cholesterol Education Program : Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
Mallion J, Siche J, Lacourcière Y : ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. Hum Hypertens 1999; 13: 657–664.
Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF : A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123–1132.
VA Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. JAMA 1970; 213: 1143–1152.
Diez J, Gonzalez A, Lopez B, Ravassa S, Fortuno MA : Effects of antihypertensive agents on the left ventricle: clinical implications. Am J Cardiovasc Drugs 2001; 1: 263–279.
Inomata T, Nishii M, Takehara H, et al: Brain natriuretic peptide-guided treatment reduces cardiovascular events of heart failure in outpatient management. Circulation 2003; 108 ( Suppl): IV–446 ( Abstract).
Wang TJ, Larson MG, Levy D, et al: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655–663.
Latini R, Masson S, Anand I, et al, for the Val-HeFT Investigators : The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292–299.
Kasama S, Toyama T, Kumakura H, et al: Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005; 45: 661–667.
Shimada H, Kitamura K, Anraku M, et al: Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res 2005; 28: 987–994.
Masson S, Latini R, Anand IS, et al, Val-HeFT Investigators : Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528–1538.
Kasama S, Toyama T, Hatori T, et al: Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 2006; 92: 625–630.
Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME : Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463–473.
Pershadsingh HA, Kurtz TW : Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27: 1015.
Vitale C, Mercuro G, Castiglioni C, et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
Miura Y, Yamamoto N, Tsunekawa S, et al: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757–758.
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW : Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003–1009.
Usui I, Fujisaka S, Yamazaki K, et al: Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 210–214.
Benndorf RA, Rudolph T, Appel D, et al: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159–1164.
Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R : Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457–464.
Nagel JM, Tietz AB, Göke B, Parhofer KG : The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006; 55: 1149–1154.
Janke J, Schupp M, Engeli S, et al: Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator−activated receptor-gamma activation. J Hypertens 2006; 24: 1809–1816.
Clasen R, Schupp M, Foryst-Ludwig A, et al: PPARgamma−activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137–143.
Moriuchi A, Yamasaki H, Shimamura M, et al: Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation. Biochem Biophys Res Commun 2007; 356: 1024–1030.
Negro R, Formoso G, Hassan H : The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957–961.
Derosa G, Cicero AF, Bertone G, et al: Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004; 26: 1228–1236.
Inoue T, Morooka T, Moroe K, Ikeda H, Node K : Effect of telmisartan on cholesterol levels in patients with hypertension—Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007; 39: 372–376.
Koulouris S, Symeonides P, Triantafyllou K, et al: Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005; 95: 1386–1388.
Wienen W, Entzeroth M, van Meel JCA, et al: A review on telmisartan: a novel, long-acting angiotensin II−receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127–156.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sasaki, T., Noda, Y., Yasuoka, Y. et al. Comparison of the Effects of Telmisartan and Olmesartan on Home Blood Pressure, Glucose, and Lipid Profiles in Patients with Hypertension, Chronic Heart Failure, and Metabolic Syndrome. Hypertens Res 31, 921–929 (2008). https://doi.org/10.1291/hypres.31.921
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.31.921
Keywords
This article is cited by
-
Chronic angiotensin receptor activation promotes hepatic triacylglycerol accumulation during an acute glucose challenge in obese-insulin-resistant OLETF rats
Endocrine (2022)
-
Telmisartan: clinical evidence across the cardiovascular and renal disease continuum
Drugs & Therapy Perspectives (2017)
-
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
Cardiovascular Diabetology (2012)
-
Do angiotensin II type 1 receptor blockers have molecular effects?
Hypertension Research (2010)
